Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) Consolidated Net Income (2021 - 2026)

HeartSciences filings provide 6 years of Consolidated Net Income readings, the most recent being -$2.0 million for Q1 2026.

  • On a quarterly basis, Consolidated Net Income rose 21.97% to -$2.0 million in Q1 2026 year-over-year; TTM through Jan 2026 was -$8.5 million, a 1.73% increase, with the full-year FY2025 number at -$8.9 million, down 32.93% from a year prior.
  • Consolidated Net Income hit -$2.0 million in Q1 2026 for HeartSciences, up from -$2.4 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$1.2 million in Q1 2022 to a low of -$2.6 million in Q1 2025.
  • Median Consolidated Net Income over the past 5 years was -$1.9 million (2024), compared with a mean of -$1.9 million.
  • Biggest five-year swings in Consolidated Net Income: tumbled 109.25% in 2022 and later grew 21.97% in 2026.
  • HeartSciences' Consolidated Net Income stood at -$1.8 million in 2022, then grew by 3.28% to -$1.7 million in 2023, then fell by 20.26% to -$2.1 million in 2024, then decreased by 11.9% to -$2.4 million in 2025, then increased by 15.41% to -$2.0 million in 2026.
  • The last three reported values for Consolidated Net Income were -$2.0 million (Q1 2026), -$2.4 million (Q4 2025), and -$2.1 million (Q3 2025) per Business Quant data.